Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ROPEGINTERFERON ALFA-2B-NJFT vs ROZANOLIXIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ROPEGINTERFERON ALFA-2B-NJFT vs ROZANOLIXIZUMAB: Safety Overview

Metric ROPEGINTERFERON ALFA-2B-NJFT ROZANOLIXIZUMAB
Total FAERS Reports 1,405 303
Deaths Reported 17 9
Death Rate 1.2% 3.0%
Hospitalizations 119 114
Average Patient Age 51.6 yrs 61.3 yrs
% Female Patients 60.0% 60.9%
Manufacturer N/A UCB, Inc.
Route N/A SUBCUTANEOUS
Marketing Status Prescription N/A